Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter … Read more
Procter & Gamble Health Limited (PGHL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.278x
Based on the latest financial reports, Procter & Gamble Health Limited (PGHL) has a cash flow conversion efficiency ratio of 0.278x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹1.72 Billion) by net assets (₹6.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Procter & Gamble Health Limited - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Procter & Gamble Health Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Procter & Gamble Health Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Procter & Gamble Health Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DRI Healthcare Trust
TO:DHT-U
|
0.053x |
|
Guangdong Wencan Die Casting Co Ltd
SHG:603348
|
0.027x |
|
Gevo Inc
NASDAQ:GEVO
|
-0.014x |
|
Malibu Boats Inc
NASDAQ:MBUU
|
0.025x |
|
Tinexta S.p.A.
LSE:0RIW
|
0.076x |
|
DOM DEVELOPMENT SE.A.ZY 1
F:6WV
|
N/A |
|
Investis Holding SA
SW:IREN
|
0.016x |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
0.025x |
Annual Cash Flow Conversion Efficiency for Procter & Gamble Health Limited (2003–2024)
The table below shows the annual cash flow conversion efficiency of Procter & Gamble Health Limited from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₹5.37 Billion | ₹1.76 Billion | 0.327x | -22.79% |
| 2023-12-31 | ₹5.38 Billion | ₹2.28 Billion | 0.424x | +34.94% |
| 2022-12-31 | ₹7.51 Billion | ₹2.36 Billion | 0.314x | +14.30% |
| 2021-12-31 | ₹6.16 Billion | ₹1.70 Billion | 0.275x | -21.74% |
| 2020-12-31 | ₹7.04 Billion | ₹2.47 Billion | 0.351x | +7.61% |
| 2019-12-31 | ₹9.06 Billion | ₹2.96 Billion | 0.327x | +485.69% |
| 2018-12-31 | ₹15.40 Billion | ₹-1.30 Billion | -0.085x | -215.68% |
| 2017-12-31 | ₹7.33 Billion | ₹536.60 Million | 0.073x | -55.87% |
| 2016-12-31 | ₹6.45 Billion | ₹1.07 Billion | 0.166x | +17.26% |
| 2015-12-31 | ₹5.92 Billion | ₹836.60 Million | 0.141x | +1483.68% |
| 2014-12-31 | ₹5.54 Billion | ₹49.50 Million | 0.009x | +937.95% |
| 2013-12-31 | ₹5.23 Billion | ₹4.50 Million | 0.001x | -99.23% |
| 2012-12-31 | ₹4.84 Billion | ₹542.60 Million | 0.112x | +280.13% |
| 2011-12-31 | ₹4.10 Billion | ₹-255.40 Million | -0.062x | -132.70% |
| 2010-12-31 | ₹3.46 Billion | ₹659.70 Million | 0.190x | +113.20% |
| 2009-12-31 | ₹4.67 Billion | ₹417.40 Million | 0.089x | +936.50% |
| 2008-12-31 | ₹4.51 Billion | ₹38.90 Million | 0.009x | -90.44% |
| 2007-12-31 | ₹4.23 Billion | ₹381.10 Million | 0.090x | -56.34% |
| 2006-12-31 | ₹3.93 Billion | ₹811.20 Million | 0.206x | -20.21% |
| 2005-12-31 | ₹2.98 Billion | ₹771.20 Million | 0.259x | -18.21% |
| 2004-12-31 | ₹2.48 Billion | ₹784.90 Million | 0.316x | -14.07% |
| 2003-12-31 | ₹1.96 Billion | ₹722.30 Million | 0.368x | -- |